Loading...
NYSE: CRL
Charles River Laboratories International, Inc.
Healthcare · Medical - Diagnostics & Research
●S&P 500 since 2021
Market Cap
$7.73B
52w High
$228.88
52w Low
$91.86
P/E
-53.57
Volume
804.82K
Outstanding Shares
49.23M
Company profile
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.
CEOJames C. Foster
SectorHealthcare
IndustryMedical - Diagnostics & Research
Employees18,700
IPO dateJun 23, 2000
Valuation
Forward P/E—
EV/EBITDA14.21
Enterprise value$12.95B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth-0.83%
Gross margin32.91%▼7.18%vs FY2024
Operating margin10.68%▲125.30%vs FY2024
ROE-4.56%▼1633.25%vs FY2024
Analyst consensus
RatingBuy
Target price$202.17▲28.68%
25
Buy
11
Hold
0
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
May 6, 2026
View
EPS
Actual vs estimate by quarter
Q2FY25
ActualEst.
$3.12
$2.50
Q3FY25
ActualEst.
$2.43
$2.32
Q4FY25
ActualEst.
$2.39
$2.33
Q1FY26
Next Est.
—
Revenue
Actual vs estimate by quarter
Q2FY25
ActualEst.
$1.03B
$968.92M
Q3FY25
ActualEst.
$1B
$987.2M
Q4FY25
ActualEst.
$994.23M
$980.1M
Q1FY26
Next Est.
—